Evaluating RAS inhibitors for advanced lung cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of novel RAS(ON) inhibitors in combination with standard cancer treatments for patients with advanced RAS-mutated non-small cell lung cancer (NSCLC). The study is structured as a platform trial with three subprotocols, each focusing on different combinations of RAS inhibitors and standard therapies. Patients with specific RAS mutations will be enrolled to determine the recommended doses and schedules for these treatments.

Why it matters

Who can join: the full rules

Inclusion criteria:

All Patients (unless otherwise noted):

* ≥ 18 years of age
* ECOG PS is 0 to 1
* Adequate organ function as outlined by the study
* Received prior standard therapy appropriate for tumor type and stage
* Must have pathologically documented, locally advanced or metastatic KRAS G12C-mutated solid tumor malignancy (not amenable to curative surgery) (Subprotocol A)
* Must have pathologically documented, locally advanced or metastatic RAS-mutated NSCLC (Subprotocol B)
* Must have pathologically documented, locally advanced or metastatic RAS G12D-mutated NSCLC (Subprotocol C and Subprotocol D)

Exclusion criteria:

All Patients:

* Primary central nervous system (CNS) tumors
* Impaired gastrointestinal (GI) function that may significantly alter the absorption of RMC drugs
* Major surgery \< 28 days of first dose
* Active or history of interstitial lung disease (ILD) or pneumonitis requiring steroids

Other inclusion/exclusion criteria may apply.

Where it's running

• Banner MD Anderson Cancer Center
  Gilbert, Arizona, United States Recruiting
• UC Davis, Davis Comprehensive Cancer Center
  Sacramento, California, United States Recruiting
• University of California, San Diego Moores Cancer Center
  San Diego, California, United States Recruiting
• UCSF Medical Center - Mission Bay
  San Francisco, California, United States Recruiting
• Stanford University - Stanford Cancer Institute
  Stanford, California, United States Recruiting
• Georgetown University Medical Center
  Washington D.C., District of Columbia, United States Recruiting

+48 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: Revolution Medicines
• Email: medinfo@RevMed.com
• Phone: 1-844-2-REVMED

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• CR-002 study in adults with advanced solid tumors

  This trial tests CR-002 as a single therapy to see if it is safe and tolerable in adults with locally advanced or metastatic solid tumors

  Recruiting at 3 sites Phase 1/2 Crescent Biopharma, Inc. · Austin, Texas and 2 other locations · NCT07909031

• NSCLC biomarker study using tumor and blood samples to link genetics with prognosis and immunotherapy response

  Researchers will test tumor tissue and blood from about 300 NSCLC patients to find genomic and immune markers that predict prognosis and response to immunotherapy.

  Recruiting at 20 sites Hellenic Cooperative Oncology Group · Limassol and 19 other locations · NCT07900581

• Wireless home prehabilitation for older adults with NSCLC awaiting lung surgery

  This study tests whether a personalized home exercise program guided by wearable devices can improve lung function for older NSCLC patients preparing for curative lung surgery.

  Recruiting West China Hospital · Chengdu, Sichuan · NCT07809763

• First-line treatment with pembrolizumab, pemetrexed, and platinum with or without zoldonrasib for metastatic non-squamous NSCLC

  This trial tests whether adding zoldonrasib to standard pembrolizumab and platinum chemotherapy helps people with untreated metastatic non-squamous NSCLC that has a RAS G12D mutation.

  Recruiting at 4 sites Phase 3 Revolution Medicines, Inc. · Anchorage, Alaska and 3 other locations · NCT07777822

• Targeted radioligand therapy for several solid tumors using DWJ155 imaging and treatment

  A phase 1 study tests [177Lu]Lu-DWJ155 for treatment and [68Ga]Ga-DWJ155 for imaging in adults with certain breast cancers, NSCLC, GEJ cancer, or bladder cancer who have not benefited from standard therapies.

  Recruiting at 6 sites Phase 1 Novartis · Omaha, Nebraska and 5 other locations · NCT07660055

• First-in-human imaging study of 68Ga-DFC413 and comparison with 68Ga-NNS309 in solid tumors

  This study tests a new radioactive imaging agent, 68Ga-DFC413, to see how it behaves in patients with several solid tumors and compares it to 68Ga-NNS309.

  Recruiting at 2 sites Phase 1 Novartis · Odense C and 1 other locations · NCT07630961

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.